22:48 uur 27-06-2019

Ultivue haalt 22 miljoen dollar op in serie C-financiering

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ultivue, een leider in innovatie in identificatie- en kwantificeringstests voor weefselbiomarkers voor laboratoriums voor translationeel en pathologisch onderzoek, heeft vandaag de sluiting aangekondigd van een C-financiering van 22 miljoen dollar, onder leiding van de nieuwe investeerder Northpond Ventures en aangedreven door bestaande investeerders waaronder ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital en Applied Ventures. De investering zal worden gebruikt om de leidende positie van Ultivue verder uit te breiden, voornamelijk door de uitbreiding van het portfolio van UltiMapper™-kits met een toenemende mate van productaanpassing. Ultivue zal ook de aanwezigheid op de internationale markt aanzienlijk vergroten door meer te investeren in verkoop, wetenschappers die de technologie in het veld kunnen toepassen en in marketing in alle regio’s met een directe focus op Azië.

Ultivue Raises $22 Million in Series C Funding

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ultivue, the innovation leader in tissue biomarker identification and quantification assays for translational and pathology research labs, today announced the close of a $22 Million Series C funding led by new investor Northpond Ventures and fueled by existing investors including ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital, and Applied Ventures. The investment will be used to further extend Ultivue’s leadership position primarily through the expansion of its portfolio of UltiMapper™ kits with an increasing level of product customization. Ultivue will also significantly accelerate its international market presence with increased investments in sales, field application scientists and marketing across all regions with an immediate focus on Asia.

“We are delighted to receive the backing of Northpond Ventures in addition to our existing investors as we advance the field of multiplex biomarker detection and analysis for tissue phenotyping,” said Michael Natan, CEO of Ultivue. “This latest round of financing sets the stage for substantial growth and allows us to continue developing the innovation to meet the evolving needs of our customers in translational and clinical research.”

“The fast market adoption of Ultivue’s reagents and services is making an impact in the field of immuno-oncology research and we are excited to work together with the current investors to drive forward the mission of tissue-based spatial phenotyping,” said Sharon Kedar, Co-Founder, Partner at Northpond Ventures.

About Ultivue

Multiplexed biomarker assays in tissue for research in personalized medicine and digital pathology.

By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution, while fitting completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper™ assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper™ assay product portfolio and menu of contract research services to provide a comprehensive set of personalized medicine solutions for oncology research as well as other therapeutic areas.

Ultivue is based in Cambridge, MA. For more information, visit www.ultivue.com.


Louis Levy



Check out our twitter: @NewsNovumpr